Stocks and Investing Stocks and Investing
Tue, July 2, 2019
Mon, July 1, 2019

Brian Abrahams Maintained (SRPT) at Buy with Increased Target to $220 on, Jul 1st, 2019


Published on 2024-10-26 14:26:19 - WOPRAI, Brian Abrahams
  Print publication without navigation


Brian Abrahams of RBC Capital, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $188 to $220 on, Jul 1st, 2019.

Brian has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Brian's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Brian


  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $190 on, Thursday, May 16th, 2019
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $165 on, Tuesday, May 14th, 2019
Contributing Sources